This technology is a nanoparticle delivery system functionalized with cationic polymers that delivers chemotherapeutics and scavenges cell-free nucleic acids to reduce inflammation, metastasis, and cognitive impairment.
Chemotherapeutic drugs such as paclitaxel and doxorubicin treat primary breast tumors but can trigger the release of cell-free nucleic acids (cfNAs) from damaged cells. These cfNAs drive chronic inflammation, contributing to tumor metastasis and long-term cognitive impairment following treatment. As a result, patients may experience persistent neurological side effects despite initial therapeutic success.
This technology is a nanoparticle delivery system made of cholesterol-modified cationic polyamidoamine (PAMAM) dendrimers that bind and scavenge cell-free nucleic acids (cfNAs). These polymeric materials self-assemble into size-controlled nanoparticles that deliver chemotherapeutics while simultaneously neutralizing cfNAs. By reducing cfNA-driven systemic inflammation, this approach limits chemotherapy-associated metastasis and cognitive impairment while maintaining anti-tumor efficacy.
This technology has been validated for both antitumor efficacy and for treating cognitive impairment in an NSG mouse model and Balb/c mouse model, respectively.
Patent Pending (WO/2025/0090489)
IR CU22225, CU19240, CU22070
Licensing Contact: Dovina Qu